Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts

INTRODUCTION: Interleukin-6 (IL-6) is an important mediator of inflammation and activation of T cells, B cells, and plasma cells. Excessive IL-6 production is linked to human diseases characterized by unregulated antibody production, including alloimmunity, where persistence of donor-specific antibo...

Descripción completa

Detalles Bibliográficos
Autores principales: Jordan, Stanley C., Ammerman, Noriko, Choi, Jua, Huang, Edmund, Najjar, Reiad, Peng, Alice, Sethi, Supreet, Sandhu, Rana, Atienza, Janet, Toyoda, Mieko, Ge, Shili, Lim, Kathlyn, Gillespie, Matthew, Zhang, Xiaohai, Haas, Mark, Vo, Ashley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039906/
https://www.ncbi.nlm.nih.gov/pubmed/35497778
http://dx.doi.org/10.1016/j.ekir.2022.01.1074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039906/
https://www.ncbi.nlm.nih.gov/pubmed/35497778
http://dx.doi.org/10.1016/j.ekir.2022.01.1074

Ejemplares similares